Can Kalvista make HAE after Pharvaris’s misstep?
A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.
Cytokine players keep the faith
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
The Sting is dead; long live the Sting
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.
The lowdown on high blood pressure
After Idorsia’s tease in resistant hypertension, data will soon emerge on other advanced assets, including long-acting RNA-based approaches.
The next generation of diabetes technology
New devices are coming, but the real advances will involve combinations.
Late-stage pain pipeline refuses to swell
Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.
Problems Facing The Current Generation Of Genetic Medicines
A new report from Evaluate Vantage looks at new approaches aiming to solve problems facing the current generation of genetic medicines.
The year the regulators meet the microbiome
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
